haxxiy on 07 April 2021
Coronavac seems to be working at 50 - 70% efficacy, perhaps even higher than the trials had suggested, in both Brazil and Chile, despite the prevalence of the P1 variant.
I wonder if this success is due to the vaccine is mostly working not because of spike antibodies, as previously assumed, but nucleocapsid and membrane antibodies. I would assume these are highly conserved antigen sites across all variants, since the bulk of evolutionary pressure lies in the n-terminal and the receptor-binding domain of the spike protein.
